Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma

The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma

Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD

Duvakitug was well tolerated and safety was consistent with the induction study

Indian pharma market grew 10.2% yoy in January 2026

Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise

Zydus receives final approval from USFDA for Ammonium Lactate Cream, 12%

Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods

Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore

Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal

Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories

BioAsia 2026 positions Telangana as a global TechBio powerhouse

BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem

OneSource bags SFDA nod for generic Ozempic in Saudi Arabia

IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY